New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Revolution Medicines, Inc.
RVMD
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

8B

Biotechnology

Next Earning date - 04 Nov 2024

8B

Biotechnology

Next Earning date - 04 Nov 2024

50.43USD
Shape0.43 ( 0.86%)
favorite-chart

Relative Strenght

92
favorite-chart

Volume Buzz

-39%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

1%

Quote Panel

Shape
Updated October 21, 2024
1W 2.94 % 1M 18.30 % 3M 5.19 % 1Y 174.67 %

Key Metrics

Shape
  • Market Cap

    8.42B


  • Shares Outstanding

    167.04M


  • Share in Float

    139.21M


  • Dividende

    0


  • Earning Date

    04 Nov 2024


  • Price Target

    50.43


  • Average Volume

    1.02M


  • Beta

    1.435


  • Range

    15.44-51.0


  • Industry

    Biotechnology


  • Website

    https://www.revmed.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

11352.80x

P/S Ratio

5.14x

P/B Ratio

0.1

Debt/Equity

-69974.0%

Net Margin

$-3.7

EPS

How RVMD compares to sector?

P/E Ratio

Relative Strength

Shape

RVMD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Piper Sandler

downgrade

Previous: Overweight

2024-07-16

Now: Neutral

Barclays

initialise

Previous: Not converted

2024-07-12

Now: Overweight

Jefferies

initialise

Previous: Not converted

2024-07-08

Now: Buy

Raymond James

upgrade

Previous: Not converted

2024-04-10

Now: Strong Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.87
vs -0.72

Q4.22

arrow
arrow

N/A

-0.63
vs -0.71

Q1.23

arrow
arrow

N/A

-0.72
vs -0.78

Q2.23

arrow
arrow

N/A

-0.92
vs -0.82

Q3.23

arrow
arrow

N/A

-0.99
vs -0.87

Q4.23

arrow
arrow

N/A

-1.14
vs -0.63

Q1.24

arrow
arrow

N/A

-0.70
vs -0.72

Q2.24

arrow
arrow

N/A

-0.81
vs -0.92

Q3.24

arrow
arrow

N/A

-0.89
vs -0.99

Q4.24

arrow
arrow

N/A

-0.97
vs -1.14

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+205%

3.4M  vs 1.1M

Q4.22

arrow
arrow

+62%

15.3M  vs 9.5M

Q1.23

arrow
arrow

-7%

7M  vs 7.6M

Q2.23

arrow
arrow

-58%

3.8M  vs 9.1M

Q3.23

arrow
arrow

-100%

NA  vs 3.4M

Q4.23

arrow
arrow

-95%

742K  vs 15.3M

Q1.24

arrow
arrow

-100%

NA  vs 7M

Q2.24

arrow
arrow

-100%

NA  vs 3.8M

Q3.24

arrow
arrow

NA

807.7K  vs NA

Q4.24

arrow
arrow

+9%

807.7K  vs 742K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-11%

-0.11
vs -0.12

Q4.22

arrow
arrow

-8%

-0.08
vs -0.11

Q1.23

arrow
arrow

-6%

-0.06
vs -0.08

Q2.23

arrow
arrow

-11%

-0.11
vs -0.06

Q3.23

arrow
arrow

-13%

-0.13
vs -0.11

Q4.23

arrow
arrow

-9%

-0.09
vs -0.13

Q1.24

arrow
arrow

-7%

-0.07
vs -0.09

Q2.24

arrow
arrow

-8%

-0.08
vs -0.07

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

141

141
vs 128

10%

Q4.22

arrow
arrow

139

139
vs 141

-1%

Q1.23

arrow
arrow

152

152
vs 139

9%

Q2.23

arrow
arrow

145

145
vs 152

-5%

Q3.23

arrow
arrow

183

183
vs 145

26%

Q4.23

arrow
arrow

200

200
vs 183

9%

Q1.24

arrow
arrow

218

218
vs 200

9%

Q2.24

arrow
arrow

227

227
vs 218

4%

Earnings Growth

Latest News